About: New Insights in Recurrent HCV Infection after Liver Transplantation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: New Insights in Recurrent HCV Infection after Liver Transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	New Insights in Recurrent HCV Infection after Liver Transplantation
Creator	Hsu, Shih-Hsien Wang, Shen-Nien Yeh, Ming-Lun
Source	Medline; PMC
abstract	Hepatitis C virus (HCV) is a small-enveloped RNA virus belonging to the Flaviviridae family. Since first identified in 1989, HCV has been estimated to infect 170 million people worldwide. Mostly chronic hepatitis C virus has a uniform natural history, from liver cirrhosis to the development of hepatocellular carcinoma. The current therapy for HCV infection consists of a combination of Pegylated interferon and ribavirin. On the other hand, HCV-related liver disease is also the leading indication for liver transplantation. However, posttransplant HCV re-infection of the graft has been reported to be universal. Furthermore, the graft after HCV re-infection often results in accelerated progression to liver failure. In addition, treatment of recurrent HCV infection after liver transplantation is often compromised by enhanced adverse effects and limited efficacy of interferon-based therapies. Taken together, poor outcome after HCV re-infection, regardless of grafts or recipients, poses a major issue for the hepatologists and transplant surgeons. The aim of this paper is to review several specific aspects regarding HCV re-infection after transplant: risk factors, current therapeutics for HCV in different stages of liver transplantation, cellular function of HCV proteins, and molecular mechanisms of HCV entry. Hopefully, this paper will inspire new strategies and novel inhibitors against recurrent HCV infection after liver transplantation and greatly improve its overall outcome.
has issue date	2013-04-23(xsd:dateTime)
bibo:doi	10.1155/2013/890517
bibo:pmid	23710205
has license	cc-by
sha1sum (hex)	43ea5663d460f9bc3ec53ceea11e85b6265a1fef
schema:url	https://doi.org/10.1155/2013/890517
resource representing a document's title	New Insights in Recurrent HCV Infection after Liver Transplantation
has PubMed Central identifier	PMC3655463
has PubMed identifier	23710205
schema:publication	Clin Dev Immunol
resource representing a document's body	covid:43ea5663d460f9bc3ec53ceea11e85b6265a1fef#body_text
is schema:about of	named entity 'risk factors' named entity 'therapy' named entity 'specific' named entity 'transplant surgeons' named entity 'virus' named entity 'inhibitors' named entity 'aspects' named entity 'HAND' named entity 'HEPATOCELLULAR CARCINOMA' named entity 'EFFICACY' named entity 'PEGYLATED' named entity 'MECHANISMS' named entity 'NOVEL' named entity 'INHIBITORS' named entity 'THERAPEUTICS' named entity 'IS A' named entity 'SMALL' named entity 'ITS' named entity 'BELONGING' named entity 'ADDITION' named entity 'INDICATION FOR' named entity 'GRAFT' named entity 'CURRENT' named entity 'NATURAL HISTORY' named entity 'RISK FACTORS' named entity 'FAMILY' named entity 'CURRENT THERAPY' named entity 'BASED' named entity 'MILLION' named entity 'SURGEONS' named entity 'OVERALL' named entity 'HEPATITIS C VIRUS' named entity 'LIMITED' named entity 'FLAVIVIRIDAE' named entity 'A MAJOR' named entity 'LIVER CIRRHOSIS' named entity 'UNIVERSAL' named entity 'INTERFERON ' named entity 'LIVER FAILURE' named entity 'OUTCOME' named entity 'UNIFORM' named entity 'WORLDWIDE' named entity 'SPECIFIC' named entity 'TREATMENT' named entity 'ENTRY' named entity '170' named entity 'INFECTION' named entity 'COMBINATION' named entity 'IDENTIFIED' named entity 'RIBAVIRIN' named entity 'HCV INFECTION' named entity 'ISSUE' named entity 'PAPER' named entity 'REVIEW' named entity 'TO INFECT' named entity 'LIVER TRANSPLANTATION' named entity 'RECURRENT' named entity 'HCV INFECTION' named entity 'INSIGHTS' named entity 'NEW' named entity 'TRANSPLANT' named entity 'INTERFERON' named entity 'NEW' named entity 'ADVERSE EFFECTS' named entity 'LEADING' named entity 'STAGES' named entity 'CHRONIC HEPATITIS C' named entity 'THERAPIES' named entity 'AIM' named entity 'POOR OUTCOME' named entity 'DEVELOPMENT' named entity 'PROTEINS' named entity 'REPORTED' named entity 'MOLECULAR' named entity 'DIFFERENT' named entity 'RECURRENT' named entity 'LIVER DISEASE' named entity 'STRATEGIES' named entity 'RNA VIRUS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software